丹参酮ⅡA磺酸钠对早期糖尿病肾病患者血清TGF-β1\Ⅳ型胶原水平的影响(3)
 |
| 第1页 |
参见附件(1429KB，2页)。
[3] Chen S, Jim B, Ziyadeh FN. Diabetic nephropathy and transforming growth factor beta : transforming our view of glomerulosclerosis and fibrosis buildup. Semin Nephrol, 2003,23(2) : 532-543.
[4] 刘志红.糖尿病肾病.中华肾脏病杂志,2000,16(2):126.
[5] Chen S,Hong S W,CruzM C,eta1.The key role of the transforming growth factor-beta system in the pathogensis of diabetic nephrothy.Ren Fail,2001,23(4):471.
[6] Teicher BA.The transforming growth factor beta Proteins:discoveries and insights.Cancer Metasis Rev,2001,20(1):l33.
[7] Hori Y, Katoh T, Hirakata M, et al. Anti-latent TGF-beta binding protein-1 antibody or synthetic oligopeptides inhibit extracellular matrix expression induced by stretch in cultured rat mesangial cells. Kidney Int,1998,53 (6) :1616-1625.
[8] Anderson S,Rennke HG,Brenner BM,et al.Nifedipine versus fosinopril in unine phrectomized diabenic rats.Kidney Int,2002,41(4):891-897.
[9] 唐锦辉,占成业.丹参酮ⅡA对大鼠肾间质纤维化的抑制作用.内科急危重症杂志,2008,14(1):16-18.
[10] Kim SK, Jung KH, Lee BC. Protective effect of Tanshinone ⅡA on the early stage of experimental diabetic nephropathy. Biol Pharm Bull, 2009, 32(2):220-224.
您现在查看是摘要介绍页，详见PDF附件(1429KB，2页)。